Growth is expected for the generic drugs and biosimilars sectors, driven by cost pressures on healthcare systems.
According to a new report from CPhI, 2018 will be a transformative year for the pharmaceutical market in Japan. The report was release ahead of CPhI Japan, which is set to take place on April 18–20, 2018 at the Big Sight Exhibition Centre, Tokyo, Japan.
Growth is expected for the generic drugs and biosimilars sectors, driven by cost pressures on healthcare systems. In a survey, 59% of domestic respondents believe that biosimilars will be the fastest growing sector. International companies are looking for opportunities to penetrate the local pharmaceutical market, but most believe that having a Japanese partner is key to overcoming obstacles such as brand loyalty and the lack of local knowledge. There could even be acquisitions in the medium term.
In an inaugural study of the perceptions of 500 pharmaceutical companies, Japan was among the top three countries in terms of reputation ranking. Japan was seen to have a higher growth potential than most European countries in the league, falling third behind Germany (first) and the United States (second). Japan also scored positively in “overall competitiveness.”
Results from the survey, however, revealed some differences in opinion between international and domestic respondents. One major difference is that domestic respondents believe that the Pharmaceutical and Medical Devices Agency (PMDA) has made effective strides in tackling the drug approval backlog, while international respondents largely disagree.
Nonetheless, Japan is an attractive market for global businesses since it joined PIC/S in 2014 and made efforts to synchronized manufacturing and quality control standards between oversea suppliers and domestic manufacturers, which have, as a result, accelerated market entry of international companies. In fact, 95% of international respondent were positive when asked about their intentions to work with Japanese partners.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Exosomes Field Advances with Milestones Achieved by EXO Biologics and ExoXpert
December 4th 2024EXO Biologics and ExoXpert, an EXO Biologics subsidiary, have received GMP certification of a European manufacturing facility for exosomes and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.